|
|
Article: Bradmer announces 2008 fourth quarter and fiscal year operational and financial results.
- Article from:
- PR Newswire
- Article date:
- March 31, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TSX: BMR
TORONTO, March 31 /PRNewswire-FirstCall/ -- Bradmer Pharmaceuticals Inc. ("Bradmer" or the "Corporation") announced its 2008 fourth quarter and fiscal year operational and financial results.
Operational Highlights
During the year ended December 31, 2008, the Company achieved the following steps for its multi-center Phase III trial of its lead drug Neuradiab(R), a treatment for glioblastoma multiforme (GBM), the most advanced form of brain cancer:
- Prepared and submitted the Company's drug manufacturing data package
and clinical dossiers to the FDA;
- Initiated enrollment in the Phase III GLASS-ART clinical ...